Erlocip 25mg, 100mg, 150mg FC tablet
PDF Leaflet Revision Date: 11 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of locally advanced or metastatic non-small cell lung cancer, bronchial adenocarcinoma, and pancreatic cancer.
Dosage (summary)
150 mg daily for NSCLC and bronchial adenocarcinoma; 100 mg daily with gemcitabine for pancreatic cancer.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
- Paediatric
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding; potential harm to the infant.
Key Drug Interactions
- CYP3A4 inducers/inhibitors
- Proton pump inhibitors
- Antacids
- Warfarin
Contraindications
- Severe hypersensitivity to erlotinib
Common side effects
- Diarrhoea
- Keratitis
- Fatigue
- Nausea
- Rash
Counselling Points
- Take at least 1 hour before or 2 hours after food
- Monitor for pulmonary symptoms
- Avoid smoking
Serious warnings
- Interstitial lung disease
- Gastrointestinal perforation
- Severe hepatic dysfunction
Important Disclaimer
The Erlocip 25mg, 100mg, 150mg FC tablet professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
